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ABSTRACT Peripheral arterial disease (PAD) now affects approximately 20% of adults older than 55 years to an estimated 
total of 27 million people in the Western World. The aim of this paper is to describe the medical management of PAD for the 
non-vascular specialist, particularly general practitioners, where PAD has now been included in the Northern Ireland Department 
of Health’s Primary Care Service Framework (Directed Enhanced Service).  
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DEFINITION
Peripheral arterial disease (PAD) is defined by the presence 
of significant narrowing of arteries distal to the arch of the 
aorta, most often due to atherosclerosis1, 2. Clinically, PAD 
most commonly affects the lower limbs as a consequence of 
arterial narrowing distal to the aortic bifurcation1, 2.  
CLINICAL PRESENTATION
PAD is initially asymptomatic. Intermittent Claudication 
(IC) is defined as reproducible lower extremity muscular 
pain induced by exercise and relieved by short periods of 
rest. It is the symptomatic expression of the inability of the 
lower limb vasculature to maintain adequate tissue perfusion 
and oxygenation during exertional activity2, 3. Although 
an ankle-brachial pressure index (ABPI) less than 0.9 
suggests arterial disease, only 10% to 30% of such patients 
will have classic symptoms of IC4. The presence of slight 
abnormalities in peripheral blood flow does not necessarily 
result in symptomatic PAD. Table 1 describes the differential 
diagnoses of lower limb exertional discomfort.    
Critical limb ischaemia is lower extremity arterial occlusive 
disease of a magnitude that potentially threatens the viability 
of the limb. Critical ischaemia (CI) is persistent rest pain 
for a period greater than two weeks duration requiring 
regular analgesia, with an ankle systolic pressure of less 
than 50mmHg or toe pressure of less than 30mmHg, with or 
without associated tissue ulceration or gangrene5.
EPIDEMIOLOGY
PAD now affects approximately 20% of adults older than 
55 years with an estimated total prevalence of 27 million 
people in North America and Europe6. The peak incidence is 
60 new cases per 10,000 persons per year with a prevalence 
of 8 million people in the United States7. In Europe, Hooi et 
al (2001) documented an overall incidence of 1.0 per 1000 
people for symptomatic PAD in the Netherlands8. 
The Framingham study, and others, documented an increasing 
prevalence of intermittent claudication (IC) with age and a 
two-fold male predominance (1.8% for women and 3.6% 
for men). However, the Edinburgh Artery Study failed to 
demonstrate any significant difference in PAD between men 
and women9. The risk of PAD increases two- to three-fold 
for every 10 year increase in age after 40 years10. More 
recently, IC was reported to be more common in men, whereas 
asymptomatic PAD and severe ischaemia were more frequent 
in women1. 
NATURAL HISTORY OF PERIPHERAL ARTERIAL 
DISEASE
Between 5% and 10% of individuals with asymptomatic 
PAD develop IC over 5 years and 75% of such patients 
will experience symptom stabilisation or improvement 
over their lifetime without intervention11. This trend occurs 
despite arteriographic evidence of disease progression in 
the majority of patients. Symptoms may then deteriorate in 
the remaining 25%, most commonly in the first year (7-9%), 
and subsequently at rates of 2% to 3% per year, resulting 
in an incidence of CI between 0.25 to 0.45 per 1000 people 
per year3. In the first 5 years following diagnosis, 5% of IC 
patients will require a therapeutic intervention, while only 2% 
to 4% will ever require a major amputation12. The Edinburgh 
Artery Study demonstrated that 28.8% of IC patients still had 
pain after 5 years, 8.2% had undergone a vascular surgical 
revascularization or amputation and that 1.4% developed 
leg ulceration9. Although PAD progression is usually slow 
and the risk of limb loss is low, approximately 20-25% 
of symptomatic PAD patients will die from coronary or 
cerebrovascular events within 5 years9, 13. For this reason, 
risk factor modification and secondary prevention treatment © The Ulster Medical Society, 2011.
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in PAD patients is as important as in patients with coronary 
and cerebrovascular disease.
MODIFIABLE RISK FACTORS
Atherosclerosis is a multifactorial disease process associated 
with the interaction of numerous risk factors. The National 
Health and Nutrition Examination Survey (1999-2000) 
analysed 2174 participants over the age of 40 and identified 
a 4.3% prevalence of PAD based on ABPI < 0.90 in either 
lower limb14. Using age and gender adjusted logistic 
regression analyses, they reported odds ratios for risk factors 
significantly associated with PAD including current smoking 
(4.46), black race (2.83), diabetes (2.71), poor kidney function 
(2.00), hypertension (1.75) and hypercholesterolaemia (1.68). 
Smoking: Smokers have a 3 times greater relative risk of 
developing IC and experience symptoms 10 years earlier 
than their non-smoking counterparts3. The Framingham study 
also showed that smokers are twice as likely to develop PAD 
as coronary artery disease15. There is also a dose-dependant 
relationship between smoking and severity of PAD16. 
Diabetes: Diabetes mellitus is strongly linked to early onset 
vascular disease, leading to premature cardiovascular events 
and mortality15. The Framingham study showed that 20% of 
IC patients have diabetes and that diabetes increases two- to 
three-fold the risk of IC. Although most reported studies do 
not stratify patients according to Type 1 and Type 2 diabetes, 
patients with both diabetes and IC have a two- to four-fold 
increased risk of a further cardiovascular event15. PAD 
prevalence increases with the duration of diabetes with 15% 
of diabetic patients affected by PAD at 10 years following 
diagnosis, rising to 45% at 20 years17. Of major concern, 
Elhadd et al (1999) reported a 25% prevalence of undetected 
Table 1 
Differential diagnoses for lower limb exertional symptomatology.
Condition Prevalence Anatomical 
Distribution
Character of 
Pain
Effect of 
Exercise
Effect of 
Rest
Effect of 
Position
Additional Factors
Thigh and 
Buttock 
Claudication
Rare Buttock, hip and 
thigh
Crampy, aching 
discomfort
Reproducible 
onset (same 
distance 
for each 
episode)
Quickly 
relieved
None Proximal pulses may 
be reduced combined 
with normal distal 
pulses
Calf Claudication 3% - 5% of the 
adult population
Calf muscles Crampy, aching 
discomfort
Reproducible 
onset
Quickly 
relieved
None May have atypical 
symptoms on exercise
Foot Claudication Rare Foot arch Severe pain on 
exercise
Reproducible 
onset
Quickly 
relieved
None Numbness can also be 
associated with pain
Venous 
Claudication
Rare Entire lower limb 
affected. Worse 
in calf.
Tight, bursting 
pain
Occurs after 
walking
Slow to 
settle
Elevation 
enhances 
recovery
Signs of deep venous 
congestion and 
oedema present. 
May have history of 
iliofemoral thrombosis
Chronic 
Compartment 
Syndrome
Rare Calf muscles Tight, bursting 
pain
Occurs after 
walking
Very slow 
to settle
Elevation 
enhances 
recovery
Tends to affect heavily 
muscled athletes
Spinal Stenosis Common Buttocks and 
posterior aspects 
of lower limb. 
Often bilateral
Pain and 
weakness
Occurs with 
exercise and 
can mimic 
claudication
Varies 
but can 
have a 
prolonged 
recovery 
time
Lumbar 
spine 
flexion 
eases 
discomfort
Exacerbated by 
standing and extending 
spine
Nerve Root 
Compression
Common Radiation of pain 
down lower limb
Sharp May be 
induced 
by sitting, 
standing or 
walking
Often 
present at 
rest
Positional 
change can 
improve 
symptoms
History of back pain
Bakers Cyst Rare Behind knee 
down calf
Tenderness 
and associated 
swelling
Occurs with 
exercise
Present at 
rest
None Usually a constant 
discomfort
Hip Arthritis Common Lateral aspect hip 
and thigh
Dull to severe 
ache
Can occur 
following 
a period of 
exercise
Not 
relieved 
quickly
Rest and 
minimal 
weight 
bearing 
helps
Symptoms can vary. 
Increased in patients 
with high BMI
Foot or Ankle 
Arthritis
Common Ankle and foot 
arch
Aching pain Variable 
onset 
following 
exercise
Not 
quickly 
relieved
Rest and 
minimal 
weight 
bearing 
helps 
Variable. Can relate to 
exercise but present 
at rest© The Ulster Medical Society, 2011.
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PAD in Scottish diabetic patients attending hospital clinics18.
There is a more rapid progression in diabetic patients with 
an 11 times higher rate of major lower limb amputation 
compared to non-diabetics and a doubling of the five-year 
mortality18. Diabetic ulcers also heal more slowly and are 
the main cause of non-traumatic lower limb amputation 
in developed countries accounting for more hospital bed 
occupancy than any other diabetic complication19. 
Hypertension: Hypertension contributes to atherosclerosis 
development, particularly in the coronary and cerebral 
circulations as well as a two- to three-fold increased risk of 
developing IC15. 
Hypercholesterolaemia: Elevated serum cholesterol, 
triglyceride and low density lipoproteins (LDL) with reduced 
high density lipoprotein levels are all implicated as important 
factors for the progression of atherosclerosis. 
Hyperhomocysteinaemia: Elevated homocysteine level 
may initiate atherosclerosis by modulating cholesterol 
biosynthesis, thus inducing other cardiovascular risk factors. 
It is considered an independently graded risk factor for 
arteriosclerotic vascular disease20. 
INVESTIGATION OF PERIPHERAL ARTERIAL 
DISEASE
Risk Factors: All patients should have a risk factor analysis 
on their first consultation, particularly smoking and blood 
pressure measurement. Assessment of haemoglobin, urea 
and electrolytes to determine baseline renal function as well 
as fasting serum glucose and lipid profiles should also be 
performed. Liver function testing should be considered at 
this stage prior to commencing pharmacological therapy, 
particularly statins.    
Vascular Flow Investigation: An assessment of peripheral 
blood flow ranges from non-invasive ankle-brachial pressure 
index, arterial duplex, computerised tomography and 
magnetic resonance imaging to conventional transfemoral 
angiography.
Ankle-Brachial Pressure Index (ABPI) is derived from the 
brachial, posterior tibial and dorsalis pedis artery systolic 
pressures which are measured using cuff occlusion by a 
sphygmomanometer and Doppler ultrasound (Figure 1). 
A resting ABPI of <0.90 indicates a haemodynamically 
significant arterial stenosis and is most often used as a 
haemodynamic definition of PAD. An ABPI <0.5 would 
suggest moderate to severe claudication while an ABPI <0.3 
is suggestive of impending critical ischaemia. An ABPI < 0.90 
is also 95% sensitive in detecting arteriogram-positive lesions 
in symptomatic individuals2. Calcification and inability 
to compress the arteries secondary to diabetes or renal 
insufficiency may result in a false elevation of ABPI > 1.4 in 
some cases2. In these patients, arterial duplex at multiple sites 
in the lower limb may identify a haemodynamically significant 
lesion2. Significant disease may also be demonstrated by the 
characteristics of the actual Doppler waveforms which range 
from normal triphasic waveforms to atherosclerotic biphasic 
and monophasic patterns which occur distal to 50% and >70% 
stenoses respectively. 
The Trans-Atlantic Inter-Society Consensus Document 
on Management of Peripheral Arterial Disease (TASC) II 
guidelines recommend that ABPI measurements should be 
performed in all patients between the age of 50-69 with a 
cardiovascular risk factor, who have exertional leg symptoms, 
who are over the age of 70 regardless of their risk-factor status 
and in all patients with a Framingham risk score of 10-20% 
(Framingham risk score is based on patient gender, age, blood 
pressure, total cholesterol and HDL levels and presence of 
smoking and diabetes)2. 
Magnetic resonance angiography (MRA) is a relatively 
safe modality offering three-dimensional images of the 
abdomen, pelvis and lower extremities (Figure 2). The 
use of techniques to minimise venous contamination have 
improved the accuracy compared to invasive angiography21. 
Although gadolinium-based contrast agents administered 
during MRA scanning may be associated with a lower risk 
of renal dysfunction when compared to iodinated contrast 
media, nephrogenic systemic fibrosis has now been reported 
which can lead to severe disability and even death through the 
induction of skin, muscle and organ fibrosis in patients with 
background renal impairment.   
Table 2 
Provisional service descriptions of the Northern Ireland 
Department of Health’s Primary Care Service Framework 
(Directed Enhanced Service) for the treatment of PAD. 
Year Target Goals
1
•  Purchase  of  equipment  for ABPI  assessment 
(doppler, sphygmomanometer).
• Training of staff to conduct ABPI assessment.
• Completion of a symptomatic PAD registry.
2
•  Completion  of  appropriate  treatment  for  all 
symptomatic PAD patients on registry.
•  Commencement  of  PAD  assessment  registry 
for at-risk patients over the age of 50 years who 
smoke. 
3
• Completion of appropriate treatment for all at-
risk PAD patients on registry.
Fig 1. Ankle-brachial index – Doppler assessment of dorsalis pedis 
which is measured using cuff occlusion by a sphygmomanometer and 
Doppler ultrasound (Super Dopplex® II Huntleigh Healthcare, UK). © The Ulster Medical Society, 2011.
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Multidetector Computerised Tomography Angiography yields 
rapid high quality imaging (Figure 3)22. Major limitations 
include iodinated contrast and radiation exposure combined 
with the requirement for careful interpretation during 
automated digital subtraction due to the presence of arterial 
wall calcification which has a Hounsfield unit value close to 
arterially opacified blood. 
Transarterial Angiography assessing the infrarenal vasculature 
remains the “gold standard” arterial imaging test, with 
concurrent therapeutic intervention potential (Figure 2). 
However, complications can arise as a consequence of the 
arterial puncture or from administration of the contrast 
material2.
Vascular Function Assessment: includes both a subjective 
assessment of quality of life combined with quantitative 
walking distances on a treadmill.
Quality of Life is an important outcome measure for 
interventions based on global and specific measures23. Generic 
health questionnaires such as the Short Form-36 (SF-36) 
evaluate QoL through measurement of physical, social and 
emotional dimensions of health. However, they are less 
sensitive in detecting subtle but clinically important treatment 
differences24. Disease-specific QoL instruments for patients 
with PAD include the Walking Impairment Questionnaire 
(WIQ) and the VascuQoL Questionnaire23, 25. 
Fig 2. Magnetic Resonance Angiogram (MRA) of the peripheral 
arterial system extending from the abdominal aorta to the pedal 
vessels which demonstrated bilateral popliteal artery occlusion 
with surrounding collateralization (Inset figure is patients pre-
operative transfemoral angiogram demonstrating bilateral popliteal 
artery occlusion).
Fig 3. Computerised tomography angiogram of the peripheral 
arterial system demonstrating proximal disease of both lower limbs 
extending from the external iliac to the superficial femoral arteries.© The Ulster Medical Society, 2011.
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Treadmill Testing provides an objective measure of walking 
capacity, performed on calibrated treadmill machines at a 
constant speed of 2mph (3.2 kph) and gradient of 10%2, 26. 
The time of onset of claudication pain is called the initial 
claudication distance (ICD) or claudication onset time (COT). 
The maximal walking performance before the patient stops 
due to pain is called the absolute claudication or maximal 
walking distance (ACD or MWD)27. Claudication patients 
have reduced walking capacities, with a 50% to 60% 
reduction in peak treadmill performance, compared to age-
matched healthy controls. A therapeutic intervention which 
results in a greater than 25% increase in both ICD and ACD 
is considered significant28.
TREATMENT OF PERIPHERAL ARTERIAL 
DISEASE
Treatment of PAD aims to improve longer-term cardiovascular 
outcomes through risk factor modification combined with 
antiplatelet and lipid lowering primary medical therapy 
whilst attenuation of lower limb symptomatology is 
mediated through walking specific pharmacological agents, 
endovascular or surgical interventions. The Vascular and 
Endovascular Units from the Belfast Health and Social 
Care Trust have issued PAD referral pathways to assist non-
vascular practitioners in their management of such patients 
(Figures 4-7).
CONSERVATIVE
Dietary therapy has beneficial effects on the occurrence and 
progression of atherosclerosis29. The National Cholesterol 
Education Program III (NCEP) report recommends a tiered 
dietary approach to weight reduction, with the further addition 
of cholesterol lowering agents if required29. 
Smokers should be strongly advised to stop through physician 
advice, group counselling sessions and nicotine replacement2. 
Smoking cessation reduces the severity of claudication and 
the risk of developing rest pain30.
Exercise significantly improves maximum walking time and 
overall walking ability in stable IC patients. The absolute or 
peak walking distance can be improved by more than 100% 
with a greater effect identified in longer-term programmes31. 
Exercise has been reported as more effective than angioplasty 
or antiplatelet therapy for improving walking time and quality 
of life, but remains similar to surgical treatment. Exercise also 
improves gait patterns in non-surgical patients32. Exercise 
programmes deliver better outcomes when supervised 
by hospital based-departments compared to home based-
programmes and if the mean duration is greater than 2 
Fig 4. Belfast Health and Social Care Trust Referral Pathway for 
screened or asymptomatic patients.
Fig 5. Belfast Health and Social Care Trust Referral Pathway for 
patients with intermittent claudication.
Fig 6. Belfast Health and Social Care Trust Referral Pathway for 
patients with critical ischaemia.
Figure 7. Belfast Health and Social Care Trust Referral Pathway 
for patients with diabetes and renal failure.© The Ulster Medical Society, 2011.
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months31. Badger et al (2007) also commented on the efficacy 
of a supervised exercise programme, which led to further 
improvements in walking distance after lower limb arterial 
bypass surgery. 
MEDICAL
PAD medical therapies include systemic cardiovascular or 
walking specific therapies.    
Systemic Cardiovascular Therapies
Antiplatelet Therapy: Antiplatelets delay the rate of PAD 
progression, reduce the need for intervention and the rate of 
graft failure following revascularisation procedures33. More 
importantly a meta-analysis of 195 placebo-controlled trials 
of antiplatelet therapy demonstrated a reduced cardiovascular 
death risk of approximately 25% in high risk patients 
including those with symptomatic PAD33. The Clopidogrel 
vs. Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) 
trial reported a 8.7% relative risk reduction for MI, stroke 
or cardiovascular death when clopidogrel (75mg/day) was 
compared to aspirin (325mg/day) in high-risk patients34. 
Aspirin (75mg) is therefore indicated in all patients with 
PAD while Clopidogrel (75mg) should be considered for 
higher risk patients particularly those with severe cardiac 
disease and diabetes. Other antiplatelet therapies including 
picotamide, triflusal and ketaserin have not been reported to 
be superior to aspirin for preventing systematic complications 
in PAD patients33.
Lipid Lowering Therapy: Statins are clearly efficacious 
in cholesterol homeostasis with additional cardiovascular 
benefits which include a 20% relative risk reduction of stroke, 
MI, vascular death and revascularisation procedures in PAD 
patients with increased baseline cholesterol levels35. Statins 
have been reported to reduce the incidence of new onset 
intermittent claudication whilst improving pain-free walking 
distances as well as reducing intimal-media thickness in 
patients with carotid artery stenosis36, 37. Current guidelines 
for lipid control state that symptomatic PAD patients should 
have their LDL lowered to <2.59 mmol/ with a target for 
further reduction down to <1.81 mmol/l in patients with 
concomitant vascular disease elsewhere2. In conjunction with 
dietary modification, statins are the primary pharmacological 
agent with fibrates and/or niacin reserved for patients with 
abnormalities in triglyceride and HDL profiles. 
Antihypertensives: Control of hypertension in PAD patients 
reduces cardiovascular co-morbidities over the medium to 
longer-term period38. All PAD patients with hypertension 
should have blood pressure controlled to <140/90 mmHg or 
<130/80 mmHg if they also have diabetes or renal insufficiency. 
Thiazides and angiotensin converting enzyme inhibitors 
are the initial antihypertensive agents to reduce the risk of 
cardiovascular disease2. Angiotensin-converting enzyme 
inhibitors, in hypertensive patients with PAD, may also improve 
walking distances without a change in ABPI measurements39. 
Although ß-blockers do not affect IC distance and are not 
actually contraindicated in PAD, a cautious approach is 
advocated for more severely affected PAD patients40.
WALKING SPECIFIC THERAPIES
Traditional PAD vasodilators such as naftidrofuryl and 
pentoxifylline have largely been superseded by cilostazol 
whereas other arterial vasodilators such as α-blockers, 
papaverine, nylidrin and nifedipine are not clinically 
efficacious in PAD41, 42.  
Cilostazol: Cilostazol (Pletal® - 100mg twice a day orally) has 
antiplatelet, antithrombotic, vasodilatory, antimitogenic and 
cardiogenic properties43. A meta-analysis showed a significant 
increase of 67% vs. 40% in ICD and 50% vs. 21% for ACD 
for oral cilostazol 100mg and placebo respectively27. A 
further meta-analysis from the Cochrane Peripheral Vascular 
Diseases Group confirmed cilostazol’s efficacy on ICD 
and ACD in patients with stable, moderate to severe IC44. 
Thompson et al (2002) and Regensteiner et al (2002) have 
also reported improvements in quality of life with cilostazol 
therapy as assessed by the SF-36 and Walking Impairment 
Questionnaires25, 27.
Cilostazol is contraindicated in congestive heart failure, 
haemostatic disorders or active bleeding. Although cilostazol 
does not alter coagulation parameters, caution is advised 
with initial clinical monitoring of patients on antiplatelet and 
warfarin therapy as well as its use in patients with moderate 
renal or hepatic dysfunction. Cilostazol is associated with 
a high frequency of side effects, particularly headache, 
diarrhoea and palpitations due to vasodilatory properties, 
occurring in up to 32% of patients27, 45. However, most of these 
effects are reported to settle within 6 weeks45, 46.
Naftidrofuryl: Naftidrofuryl (Praxilene®) has vasodilatory 
effects, improving tissue oxygenation and muscle metabolism2. 
In a meta-analysis of 888 patients with IC, naftidrofuryl 
increased pain-free walking distance by 26% compared to 
placebo47. Patients with IC who have a poor quality of life may 
be considered for treatment with naftidrofuryl2, 48. 
Pentoxifylline:  Pentoxifylline (Trental®) produces dose-
related haemorrheologic effects, lowers blood viscosity and 
improves erythrocyte flexibility. Although pentoxifylline is 
associated with modest increases in walking distance over 
placebo, the overall clinical efficacy is unclear. It is no longer 
recommended for use in PAD patients2, 48.
Inositol and Cinnarizine: Inositol nicotinate causes 
vasodilation, lysis of fibrin, a mild hypolipidaemic effect 
and inhibition of oxidative metabolism in hypoxic tissues. 
Cinnarizine acts via antagonism of vasoconstrictive 
substances such as noradrenaline, serotonin and angiotensin49. 
Although trials for these agents suggested efficacy by 
improving walking distances, their overall methodology 
was poor and have not shown clear evidence of benefit over 
placebo48. 
Alternative Peripheral Vasodilators and Treatments: 
Ticlodipine and ginkgo biloba special extract (Egb 761) 
significantly increase pain-free walking distance50, 51. 
Assessment of angiogenic stimulation of new collateral 
channels by growth factors, autologous bone marrow cells 
and transcription factor gene therapy modalities are currently 
being evaluated52-54. Although dietary supplementation 
with B-vitamins and / or folate has been shown to lower 
homocysteine levels, high-level evidence for beneficial effects 
in PAD patients in terms of preventing cardiovascular events 
is lacking and such therapy is not recommended55.  © The Ulster Medical Society, 2011.
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THERAPEUTIC INTERVENTION
Revascularisation should be considered in patients with 
critical limb ischaemia or severely debilitating claudication 
symptoms that persist despite maximal medical treatment. 
Although operative arterial bypass appears to have a better 
long term patency, the risks of surgery are significantly greater 
when compared to endovascular interventions in terms of 
mortality, major morbidity and return to the normal activities 
of daily living.
Endovascular
The technical success of percutaneous transluminal 
angioplasty (PTA) and/or stenting for proximal lesions in the 
iliac artery exceeds 90% with reported variations between 
80% and 100% depending on the presence of either long or 
focal stenotic iliac lesions respectively2. Five year primary 
patency rates range between 64% and 75% for all cases with 
a higher rates of 79% reported for claudicants2, 56, 57. 
Endovascular treatment of infrainguinal disease is also 
associated with a low morbidity and mortality with a technical 
and clinical success rate of PTA for femoropopliteal stenoses 
exceeding 95%2. However, longer term outcomes are lower 
compared to proximal iliac interventions with 5 year patency 
rates of 55% (range 52-62%) and 42% (range 33-51%) for 
femoropopliteal stenoses and occlusions respectively2. 
Although PTA improves symptomatology and median ACD 
at 6-months in patients with mild to moderate claudication, 
longer term benefits are limited with no significant difference 
in walking distances or quality of life at 2 or 6 years post-
PTA58. Independent risk factors for re-stenosis include the 
disease severity (claudication vs. critical ischaemia), the 
actual length of the stenosed / occluded segment and the 
quality of the distal outflow (run-off) vessels. 
Surgical 
Surgical intervention is indicated for critical limb ischaemia 
where the primary goal is to relieve pain, encourage ulcer 
healing, prevent limb loss and improve patient function, 
quality of life and survival2. Surgical intervention may also 
be considered in intermittent claudication in patients with 
proximal lesions or deteriorating symptomatology despite 
best medical therapy and endovascular intervention. Although 
surgical procedures improve medium to long-term outcome 
rates compared to endovascular intervention, they carry a 
higher early post-procedural complication rate2, 59, 60. 
An aortobifemoral arterial bypass is usually recommended 
for diffuse aortoiliac disease with limb-based patency rates 
for patients with claudication of 91.0% and 86.8% at 5 
and 10 years, respectively, as compared with 87.5% and 
81.8% for patients with critical limb ischemia59. In higher 
risk patients with medical co-morbidities, extra-anatomical 
bypass modalities include femoro-femoral or axillo-femoral 
arterial conduits. However, these routes have a lower success 
rate with 5 year patency rates between 51% and 75%2. 
Infrainguinal arterial bypass requires uncompromised inflow 
at the proximal anastomosis, preferably to a native artery 
rather than graft. A satisfactory distal run-off vessel is the 
most important determinant of longer-term patency which 
ranges between 35% for prosthetic material to 60% for vein 
grafts over 5 years2. 
IMPLICATIONS FOR NORTHERN IRELAND
General Practitioners in Northern Ireland participate in 
the Quality and Outcomes Framework which incentivises 
a number of activities to enhance patient outcomes. The 
Department of Health is currently drafting a Cardiovascular 
Service Framework including a care pathway from prevention, 
promotion, protection of health and wellbeing, to appropriate 
assessment, diagnosis, treatment and care provision, 
rehabilitation and end of life care based on evidence from 
established sources such as the National Institute of Clinical 
Excellence. The Northern Ireland Department of Health’s 
Primary Care Service Framework (Directed Enhanced 
Service) is now developing standards which will cover risk 
assessment for those patients who have a high risk of or who 
have PAD61. 
Provisional service descriptions as described in Table  2 
suggest the initial training of staff members in the assessment 
of PAD and the development of two disease registers to 
account for all patients with PAD followed by a second 
phase to incorporate patients greater than 50 years of age 
at risk of peripheral and cardiovascular disease particularly 
those who smoke. Finally, treatment protocols should then be 
implemented for patients on both registries61.
CONCLUSION
Peripheral arterial disease (PAD) now affects approximately 
20% of adults older than 55 years. However, less than 30% 
of patients diagnosed with PAD based on the ankle-brachial 
index will have classic symptoms of IC. Asymptomatic and 
patients able to walk greater than 100 yards should be initially 
managed in the community with risk factor modification, 
peripheral arterial examination combined with the calculation 
of ankle-brachial indices. All patients should be considered 
for antiplatelet and lipid lowering therapies. Diabetic 
patients should also receive foot care advice. Symptomatic 
patients able to walk further than 100 yards require walking-
specific medication such as cilostazol for a period of three 
months. Tertiary referral should be reserved for refractory 
symptomatology despite maximal conservative management 
in the community and short distance claudication (<100 
yards). Critical limb ischaemia warrants urgent referral.    
The authors have no conflict of interest.
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